Buscar resultados de ensayos clínicos
Charcot-Marie-Tooth Disease Type 1 - 24 Studies Found
Estado | Estudiar |
Not yet recruiting |
Nombre del estudio: Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers Condición: Charcot-Marie-Tooth Disease Type 1A Fecha: 2015-10-30 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A Condición: Charcot-Marie-Tooth Type 1A Neuropathy Fecha: 2012-11-16 |
Active, not recruiting |
Nombre del estudio: Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) Condición: Charcot-Marie-Tooth Disease Type 1A Fecha: 2015-09-28 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) Condición:
|
Recruiting |
Nombre del estudio: Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Condición: Charcot-Marie-Tooth Disease, Type IA Fecha: 2016-12-26 Intervenciones: Drug: PXT3003 Liquid oral solution, 5 mL bid for 9 consecutive months |
Completed |
Nombre del estudio: Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A Condición:
Intervenciones: |
Recruiting |
Nombre del estudio: Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Condición: Charcot-Marie-Tooth Disease Fecha: 2017-04-12 Intervenciones: Drug: ACE-083 Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solutio |
Completed |
Nombre del estudio: High Dose Ascorbic Acid Treatment of CMT1A Condición: Charcot-Marie-Tooth Disease, Type Ia Fecha: 2007-06-08 Intervenciones:
|
Completed |
Nombre del estudio: Ascorbic Acid Treatment in CMT1A Trial (AATIC) Condición:
Fecha: 2006-01-03 Intervenciones:
|
Recruiting |
Nombre del estudio: SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Condición:
|